Drugs / Haemophilus influenzae type b (Hib)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03574389 Comparator | Jun 2018 → Aug 2021 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haemophilus influenzae type b (Hib) | “older cohorts were randomized 2:1 to PCV13 or Haemophilus influenzae type b (Hib) vaccine using age-appropriate schedules.” PMID 37549923 ↗ Aug 2023 |
| Known as | Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574389 ↗ |
| Modality | Vaccine | “Haemophilus influenzae type b (Hib) vaccine” PMID 37549923 ↗ Aug 2023 |
| Route | Intramuscular | “suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose” NCT03574389 ↗ |